Long COVID Patterns in the RECOVER-Adult Study
November 21, 2025
Brand Name :
N/A
Synonyms :
crisugabalin
Class :
Voltage Gated Calcium Channel inhibitor
Dosage Forms and Strengths
The drug is being investigated in the treatment of Postherpetic Neuralgia
Not determined Â
Refer to the adult dosing regimenÂ
Actions and spectrum:Â Â
Crisugabalin belongs to a class of voltage-gated N-type calcium channel blocker. Â
It acts by binding and blocking specific channels in nerve cells which are known as N-type calcium channels. Â
None
Black Box Warning:Â
None Â
Contraindication/Caution:Â Â
The drug is contraindicated in following situations:Â Â
HypersensitivityÂ
Suicidal ideation and behavior  Â
Severe depression and anxietyÂ
Pregnancy Warnings:Â Â
Pregnancy category: N/AÂ Â
Lactation:Â Â
Excretion of the drug in human breast milk is unknown Â
Pregnancy Categories:Â Â Â Â
Category A: Satisfactory and well-controlled studies show no evidence of risk to the fetus in the first trimester or in the later trimester.   Â
<b>Category B: No evidence of risk to fetus found in animal reproduction studies and there are not enough studies on pregnant women.   Â
Category C: Adverse effects on the fetus found with evidence in animal reproduction studies and no adequate evidence for an effect in humans, care must be taken for potential risks in pregnant women.   Â
Category D: There is adequate data available with sufficient evidence of human fetal risk from various platforms, but despite potential risks may be used only in emergency cases for potential benefits.   Â
Category X: Drugs listed in this category clearly outweigh risks over benefits. These category drugs should be prohibited for pregnant women.   Â
Category N: There is no data available for the drug under this category.
Pharmacology:Â Â
Crisugabalin shows promise for treating epilepsy and neuropathic pain by targeting N-type calcium channels in nerve cells. Â
Pharmacodynamics:Â Â
Crisugabalin prevents calcium ions from entering the neuron. Â
It helps to suppress the generation and propagation of unwanted signals which leads to therapeutic benefits.  Â
Pharmacokinetics:Â
Limited information available on ADME. Â
Administration:Â Â
The route of administration for crisugabalin is not well known. Â
Patient information leaflet Â
Generic Name: crisugabalin Â
Why do we use crisugabalin? Â
Crisugabalin shows promising results in investigation with potential applications in treating various neurological conditions.Â